Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

New application of malignant B-cell lymphoma antibody medicament

A lymphoma-specific technology, applied in the direction of antibodies, drug combinations, anti-tumor drugs, etc., can solve the problems of easy recurrence, uncertain effect on relapsed patients, and high price

Active Publication Date: 2013-04-17
优锐生物医药科技(深圳)有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, chemotherapy is the main treatment for NHL, but the short-term side effects of chemotherapy are obvious, and the effect on relapsed patients is not sure, and the effect of general chemotherapy combination scheme is not good; Diagnosis, very easy to relapse, need to be combined with chemotherapy; bone marrow transplantation is difficult to carry out due to reasons such as difficulty in matching, rejection, and high price
However, the current research of this drug is limited to the application of tumor treatment, and the application of other diseases still needs to be developed and expanded.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of malignant B-cell lymphoma antibody medicament
  • New application of malignant B-cell lymphoma antibody medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Preparation of lymphoma-specific humanized antibody against HLA-DR10

[0027]Using the mouse myeloma cell line NSO-clym with the preservation number CCTCC No. 200405 recorded in the Chinese patent (patent number: 200410053872.0), inoculate the cell line in SFM containing 10% serum and not containing L-glutamine culture medium at 37°C, 5% CO 2 Cultivate in an incubator, collect the culture supernatant, and load the filtered cell-free supernatant onto the FineLINE column filled with MabSelect at a concentration of 30 mg / ml. Immediately after elution, the eluate was neutralized to pH 6.8-7.0 with potassium phosphate. Then it was detected by gel filtration, and the result showed that the purity was above 95%. The product was sequenced, and the result was that the amino acid sequence of the heavy chain variable region of the antibody was SEQ ID NO: 1, and the amino acid sequence of the light chain variable region was SEQ ID NO: 2, which met expectations. The met...

Embodiment 2

[0028] Example 2 131 Preparation of I-labeled lymphoma-specific humanized antibody against HLA-DR10

[0029] Using chloramine-T iodide labeling method, the 131 I was labeled on the lymphoma-specific humanized antibody against HLA-DR10 obtained in Example 1, and the radioactive specific activity of the product was 11 mCi / mg. The affinity constant Ka=3.40×10 of the monoclonal antibody was detected by the method of Example 1. 8 mol -1 .

Embodiment 3

[0030] Example 3 Pharmacodynamic study of lymphoma-specific humanized antibody against HLA-DR10 in the treatment of leukemia

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new application of a malignant B-cell lymphoma antibody, and discloses an application of an anti-HLA-DR10 lymphoma specific humanized antibody in preparation of medicaments for treating leukemia; the anti-HLA-DR10 lymphoma specific humanized antibody comprises a heavy chain and a light chain, wherein the heavy chain contains a constant region; a variable region of the heavy chain has an amino acid sequence of SEQ ID NO:1; the light chain contains a constant region; a variable region of the light chain has an amino acid sequence of SEQ ID NO:2; and the heavy chain and the light chain are connected through disulfide bonds. The invention further expands the new application of the anti-HLA-DR10 lymphoma specific humanized antibody in the treatment of leukemia, and brings good news for patients with leukemia.

Description

technical field [0001] The present invention relates to novel uses of known malignant B-cell lymphoma antibodies. Background technique [0002] Malignant lymphoma (ML) is a malignant tumor originating from lymph nodes and extralymphatic lymphoid tissues. ML can be divided into two categories: Hodgkin's lymphoma (HD) and non-Hodgkin's lymphoma (NHL). In my country, NHL patients account for 85-90% of new cases of malignant lymphoma. In NHL, the incidence of low-grade lymphoma with good prognosis is low in my country, accounting for about 5% of NHL; while the incidence of high-grade lymphoma with poor prognosis is relatively high, accounting for about 30% of NHL. The survey shows that with the passage of time and the development of social economy, malignant lymphoma presents an increasing trend, in which HD is relatively stable, while the morbidity and mortality of NHL are increasing. The etiology and pathogenesis of non-Hodgkin's lymphoma have not yet been determined, and it...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/02
Inventor 倪健潘健许国贞
Owner 优锐生物医药科技(深圳)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com